FDA Approval of Pemigatinib and Update From the STAMPEDE Trial
Sep 02, 2022•11 min•Ep. 158
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
This week, we're covering the FDA approval of pemigatinib for patients with myeloid or lymphoid neoplasms and an FGFR1 rearrangement. We'll also discuss a long-term update from the STAMPEDE trial of radiotherapy in prostate cancer.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Pemigatinib for Patients With Myeloid/Lymphoid Neoplasms and FGFR1 Rearrangement
Long-Term Benefit of Radiotherapy Confirmed in Advanced Prostate Cancer: STAMPEDE Trial Follow-up
To listen to more podcasts from ASCO, visit asco.org/podcasts.
For the best experience, listen in Metacast app for iOS or Android